- Home
- MTN vs TGTX Comparison
MTN vs TGTX Comparison
Compare MTN & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTN
- TGTX
- Stock Information
- Founded
- MTN 1997
- TGTX 1993
- Country
- MTN United States
- TGTX United States
- Employees
- MTN N/A
- TGTX N/A
- Industry
- MTN Services-Misc. Amusement & Recreation
- TGTX Biotechnology: Pharmaceutical Preparations
- Sector
- MTN Consumer Discretionary
- TGTX Health Care
- Exchange
- MTN Nasdaq
- TGTX Nasdaq
- Market Cap
- MTN 6.1B
- TGTX 5.5B
- IPO Year
- MTN 1997
- TGTX 1995
- Fundamental
- Price
- MTN $152.46
- TGTX $33.65
- Analyst Decision
- MTN Buy
- TGTX Strong Buy
- Analyst Count
- MTN 9
- TGTX 6
- Target Price
- MTN $176.00
- TGTX $47.50
- AVG Volume (30 Days)
- MTN 830.4K
- TGTX 1.5M
- Earning Date
- MTN 12-08-2025
- TGTX 11-04-2025
- Dividend Yield
- MTN 5.83%
- TGTX N/A
- EPS Growth
- MTN 23.64
- TGTX N/A
- EPS
- MTN 7.53
- TGTX 0.36
- Revenue
- MTN $2,964,347,000.00
- TGTX $454,069,000.00
- Revenue This Year
- MTN $2.72
- TGTX $82.13
- Revenue Next Year
- MTN $3.48
- TGTX $49.01
- P/E Ratio
- MTN $20.24
- TGTX $92.64
- Revenue Growth
- MTN 2.74
- TGTX 30.96
- 52 Week Low
- MTN $129.85
- TGTX $22.61
- 52 Week High
- MTN $199.45
- TGTX $46.48
- Technical
- Relative Strength Index (RSI)
- MTN 51.40
- TGTX 48.14
- Support Level
- MTN $148.51
- TGTX $34.01
- Resistance Level
- MTN $152.85
- TGTX $35.52
- Average True Range (ATR)
- MTN 4.50
- TGTX 1.28
- MACD
- MTN 0.07
- TGTX -0.24
- Stochastic Oscillator
- MTN 53.23
- TGTX 16.02
About MTN Vail Resorts Inc.
Vail Resorts Inc Bhd is a resorts and casinos company that operates mountain resorts and ski areas. The company has three business segments that include Mountain, Lodging, and Real Estate. The Mountain segment operates numerous ski resort properties that offer a variety of winter and summer activities, such as skiing, snowboarding, snowshoeing, hiking, and mountain biking. The Lodging segment owns and operates hotels and condominiums. The Real Estate segment owns, develops, and leases real estate, typically near its other properties. The company generates the vast majority of its revenue within the United States.
About TGTX TG Therapeutics Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.